Home › NDC Lookup › RxCUI directory › RxCUI 1602115

Empagliflozin 10 MG / linagliptin 5 MG Oral Tablet [Glyxambi] — RxCUI 1602115

Name: Empagliflozin 10 MG / linagliptin 5 MG Oral Tablet [Glyxambi] (RxCUI 1602115)
Creator: Brian Staiger, PharmD

RxNorm drug concept · Semantic branded drug

RxCUI 1602115 Semantic branded drug · SBD ● Current RxNorm concept 2 FDA products 6 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by Dr. Brian Staiger, PharmD

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI1602115

Official nameEmpagliflozin 10 MG / linagliptin 5 MG Oral Tablet [Glyxambi]

Concept typeSemantic branded drug (SBD)

RxNorm statusCurrent RxNorm concept

Also known asGlyxambi 10 MG / 5 MG Oral Tablet

FDA products mapped2

Package NDCs mapped6

Reported Medicaid activity (SDUD)7,441 prescriptions · 22 state & territory Medicaid programs · latest period Q4 2025

RxNorm release07/06/2026

Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Linagliptin: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist

Tradjenta helps your body manage blood sugar more effectively after meals. It works by protecting natural hormones in your gut — called incretins — that normally get destroyed too...
What exactly does Tradjenta do for my diabetes?
You take Tradjenta once a day — the exact time is less important than being consistent. The good news is that food doesn't really affect how well it works, so you can take it with...
Do I have to take it at a specific time of day, and does food matter?

📖 Read our full Linagliptin guide →

🕸️ Concept Web — How Empagliflozin 10 MG / linagliptin 5 MG Oral Tabl... Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.

This page's concept Empagliflozin 10 MG / linagliptin 5 MG Oral Tablet [Glyxambi] RxCUI 1602115 Semantic branded drug · SBD

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

Ingredients 3

The active substance itself — no strength, form, or brand attached yet.
- Empagliflozin 1545653 IN
- Linagliptin 1100699 IN
- Empagliflozin / linagliptin 1598392 MIN
Brand names 1

The same medicine's trade names. A brand name alone says nothing about strength or form.
- Glyxambi 1602110 BN
Dose forms 9

The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.
- Empagliflozin / linagliptin Oral Tablet 1602108 SCDF
- Empagliflozin / linagliptin Oral Product 1602106 SCDG
- Empagliflozin / linagliptin Pill 1602107 SCDG
- Empagliflozin / linagliptin Oral Tablet [Glyxambi] 1602112 SBDF
- Glyxambi Oral Product 1602113 SBDG
- Glyxambi Pill 1602114 SBDG
- Oral Tablet 317541 DF
- Oral Product 1151131 DFG
- +1 more in this family
Clinical & branded drugs 4

Ingredient + strength + dose form. These are the concepts real FDA products actually carry.
- Empagliflozin 10 MG / linagliptin 5 MG Oral Tablet 1602109 SCD
- Empagliflozin 10 MG 1545654 SCDC
- Linagliptin 5 MG 1100700 SCDC
- Empagliflozin 10 MG / linagliptin 5 MG [Glyxambi] 1602111 SBDC

Showing up to 8 concepts per family — 16 of 17 stored related concepts drawn.

These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

Empagliflozin 10 MG / linagliptin 5 MG Oral Tablet SCD · 1602109
Empagliflozin 10 MG SCDC · 1545654
Linagliptin 5 MG SCDC · 1100700
Empagliflozin / linagliptin Oral Tablet SCDF · 1602108
Empagliflozin / linagliptin Oral Product SCDG · 1602106
Empagliflozin / linagliptin Pill SCDG · 1602107

Brand-Name Concepts

Empagliflozin 10 MG / linagliptin 5 MG [Glyxambi] SBDC · 1602111
Empagliflozin / linagliptin Oral Tablet [Glyxambi] SBDF · 1602112
Glyxambi Oral Product SBDG · 1602113
Glyxambi Pill SBDG · 1602114
Glyxambi BN · 1602110

📦 FDA Products & Package NDCs

2 products · 6 package NDCs

6 package NDCs map to RxCUI 1602115 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.

Package NDC	Package	Brand / generic name	Labeler	Marketing start
00597-0164-30	30 TABLET, FILM COATED in 1 BOTTLE (0597-0164-30)	Glyxambi	Boehringer Ingelheim Pharmaceuticals, Inc.	2015-01-30
00597-0164-39	30 BLISTER PACK in 1 CARTON (0597-0164-39) / 1 TABLET, FILM...	Glyxambi	Boehringer Ingelheim Pharmaceuticals, Inc.	2015-01-30
00597-0164-90	90 TABLET, FILM COATED in 1 BOTTLE (0597-0164-90)	Glyxambi	Boehringer Ingelheim Pharmaceuticals, Inc.	2015-01-30
00597-0182-30	30 TABLET, FILM COATED in 1 BOTTLE (0597-0182-30)	Glyxambi	Boehringer Ingelheim Pharmaceuticals, Inc.	2015-01-30
00597-0182-39	30 BLISTER PACK in 1 CARTON (0597-0182-39) / 1 TABLET, FILM...	Glyxambi	Boehringer Ingelheim Pharmaceuticals, Inc.	2015-01-30
00597-0182-90	90 TABLET, FILM COATED in 1 BOTTLE (0597-0182-90)	Glyxambi	Boehringer Ingelheim Pharmaceuticals, Inc.	2015-01-30

Observed labelers: Boehringer Ingelheim Pharmaceuticals, Inc. (6) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7

openFDA export observedJul 14, 2026

RxNorm release07/06/2026

Methodology2026-07-full-catalog-v1

A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.

This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.